ACT receives patent for its single-blastomere technology Advanced Cell Technology.

Furthermore, this IP security follows on the issuance of a wide patent relating to ACT’s creation and therapeutic use of Retinal Pigment Epithelial cells in 2010 2010. We are eagerly anticipating the beginning of the two Phase 1/2 clinical trials in the first half of the year.’ Take action has been issued clearance from the FDA to proceed with two Stage 1/2 scientific trials in the U.S.. ACT receives patent for its single-blastomere technology Advanced Cell Technology, Inc. , a head in neuro-scientific regenerative medication, announced today that it has been released a patent on its ‘single-blastomere’ technique.’ The single-blastomere technology uses a one-cell biopsy approach similar to pre-implantation genetic analysis , which is widely used in the in vitro fertilization procedure and does not hinder the embryo’s developmental potential.D., chief scientific officer of ACT, stated, ‘This patent issuance represents recognition of the invention underlying our single-blastomere technology.And, that the task is safe with an extremely low complication rate fairly. However, like any invasive procedure, weight-loss medical procedures includes recovery and risks period, and it could be expensive. The cost of weight-loss surgery varies, however the U.S. National Institute of Diabetes and Digestive and Kidney Illnesses estimates the cost is generally between $20,000 and $25,000. Insurance coverage for the process depends on the insurance company.